Patrick Hwu
Affiliations: | University of California, Irvine, Irvine, CA |
Area:
Dendrite Regeneration, Neurobiology, GeneticsGoogle:
"Patrick Hwu"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Todd C. Holmes | research assistant | UC Irvine | ||
| Katherine L. Thompson-Peer | grad student | 2019- | UC Irvine | |
| Marcelo Wood | grad student | 2019- | UC Irvine | |
| (co-mentor) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hickman A, Koetsier J, Kurtanich T, et al. (2022) LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. The Journal of Clinical Investigation |
| Saberian C, Amaria RN, Najjar AM, et al. (2021) Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Journal For Immunotherapy of Cancer. 9 |
| Nave C, Roberts L, Hwu P, et al. (2021) Weekend light shifts evoke persistent Drosophila circadian neural network desynchrony. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience |
| Ascierto PA, Puzanov I, Agarwala SS, et al. (2020) Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). Journal of Translational Medicine. 18: 346 |
| Diab A, Tannir NM, Bentebibel SE, et al. (2020) Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery |
| Saberian C, Amaria R, Haymaker C, et al. (2020) 311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma Journal For Immunotherapy of Cancer. 8: A338-A338 |
| Tsimberidou A, Guenther K, Alpert A, et al. (2020) 293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) Journal For Immunotherapy of Cancer. 8: A320-A320 |
| Peng W, Williams LJ, Xu C, et al. (2019) Anti-OX40 antibody directly enhances the function of tumor-reactive CD8 T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Ludford K, Johnson DH, Hennegan T, et al. (2019) Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. Journal of Clinical Oncology. 37: 9554-9554 |
| Mitra A, Andrews MC, Roh W, et al. (2019) Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy Cancer Research. 79: 3776-3776 |